T1	Participants 120 151	inguinal herniorrhaphy patients
T2	Participants 424 466	patients undergoing inguinal herniorrhaphy
T3	Participants 685 759	adults undergoing elective, outpatient, unilateral inguinal herniorrhaphy.
T4	Participants 1338 1450	Fifty-five subjects completed the study. Twenty-six patients received rofecoxib and 29 patients received placebo
